The antiangiogenic efficacy of NGR-modified PEG–DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats
Authors:
- Wan-Liang LuWLWan-Liang Lu
- Qiang ZhangQZQiang Zhang
- 23 July 2010
- journal article
- research article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 19 (5) , 382-390
Abstract
Aminopeptidase N (APN), recognized by Asn-Gly-Arg (NGR) peptides, is expressed in the pericytes associated with the BBB, and the main objective of this study is to confirm the hypothesis that NGR-modified DSPE–PEG micelles containing paclitaxel (NGR-M-PTX) can bind to and kill brain tumor angiogenic blood vessels and penetrate into the brain tumor interstitial space, resulting in direct cell death. NGR-M-PTX is prepared by a thin-film hydration method. The in vitro targeting characteristics of NGR-modified micelles on BMEC (murine brain microvascular endothelial cells) were investigated. The effect of NGR-M-PTX on BMEC proliferation and the cytotoxicity of NGR-M-PTX in C6 glioma cells were also tested. The antitumor activity NGR-M-PTX was evaluated in C6 glioma tumor–bearing rats in vivo. The particle size of NGR-M-PTX was approximately 54.2 nm. The drug encapsulation efficiency of NGR-M-PTX was 82.11 ± 2.82%. The cellular coumarin-6 level of NGR-M-coumarin-6 in the BMEC was about 2.2-fold higher than that of M-coumarin-6. BMEC proliferation was significantly inhibited by NGR-M-PTX. NGR-M-PTX had a much lower IC50 value than M-PTX and free drug. The growth of C6 glioma tumor was markedly inhibited by NGR-M-PTX compared with Taxol. In conclusion, our results show that antiangiogenic therapy using NGR-M-PTX exhibits potent in vivo antitumor activity in a C6 glioma–bearing animal model.Keywords
This publication has 33 references indexed in Scilit:
- Active targeting schemes for nanoparticle systems in cancer therapeuticsAdvanced Drug Delivery Reviews, 2008
- Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effectsAnti-Cancer Drugs, 2007
- PPARγ‐dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF)International Journal of Cancer, 2005
- Irreversible Inhibition of CD13/Aminopeptidase N by the Antiangiogenic Agent CurcuminChemistry & Biology, 2003
- A doxorubicin–CNGRC-peptide conjugate with prodrug propertiesBiochemical Pharmacology, 2002
- Progenitor cells and glioma formationCurrent Opinion in Neurology, 2001
- Anti-cancer activity of targeted pro-apoptotic peptidesNature Medicine, 1999
- A new approach to fighting cancer?Proceedings of the National Academy of Sciences, 1998
- Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse ModelScience, 1998
- Fighting Cancer by Attacking its Blood SupplyScientific American, 1996